Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Glioblastoma 3Meningeal Carcinomatosis 1Glioma 1

Interventions

Magnetic Resonance Spectroscopy 76Temozolomide 73Specimen Handling 49Radiotherapy 43Radiosurgery 32Cyclophosphamide 27Bevacizumab 26Radiation 25pembrolizumab 24Biopsy 23Nivolumab 21Carboplatin 16X-Rays 14fludarabine 13Lomustine 13Ipilimumab 13Surgical Procedures, Operative 12Irinotecan 12Vincristine 11Topotecan 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9abemaciclib 9lutetium Lu 177 dotatate 8Immunoglobulin G 8Etoposide 8Doxorubicin 8AZD 6244 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
azeliragon × CNS × 90 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡